Clinical Trial

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-14
notable Trial sites reduced: 9 -> 4 locations 2026-08-14
Trial Details
NCT Number NCT07593092
Lead Sponsor Xencor, Inc.
Conditions Ovarian Cancer
Enrollment 90 participants
Start Date 2026-06-30
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13